Can●Sense
innovation in cancer diagnostics

CanSense is developing an accurate, rapid, non-invasive diagnostic for the early detection of Bowel Cancer using Spectroscopy and AI-based technologies.

It is a simple blood test which can significantly reduce bowel cancer mortality. Speeding up the diagnosis and treatment process for those at greatest risk, whilst significantly reducing patients subjected to unnecessary colonoscopies and reducing the healthcare burden.

Bowel Cancer is increasing in both the developed and non-developed world and increasing within the young – creating a significant growing socio-economic burden.

- Bowel Cancer is the 3rd most common cancer globally
- 1.8M new cases and 896,000 deaths occur every year
- Global burden of Bowel Cancer is expected to rise by 60% by 2030
- 19M US and 1.43M UK colonoscopies performed last year and growing

Thousands of bowel cancer deaths could be prevented every year through earlier diagnosis of this disease. This is a potentially game changing innovation in terms of population-based access to a affordable, convenient and acceptable test.

Prof Tom Crosby
OBE National Cancer Clinical Director for Wales, Clinical Lead Transforming Cancer Services

CanSense Blood test:
- ✔ Detects cancer & precancer
- ✔ Improves patient outcomes
- ✔ Cost effective solution
- ✔ Empowers clinicians decision making for rapid and accurate triage
- ✔ Streamlines treatment pathways
- ✔ Increased patient acceptability
- ✔ Tackles inequity of diagnoses

STAGE	5Y SURVIVAL
I	95%
II	80%
III	65%
IV	5%

Early diagnosis significantly reduces the mortality rate. Bowel cancer is often diagnosed too late with 60% presenting at stages III or IV. We believe in detecting & diagnosing cancer early – when it is treatable and curable.

Covid-19 has highlighted the need for accurate, accessible (Primary Care) and affordable diagnostics. Current methods of testing and screening are failing, effective testing within oncology is critical – now more than ever.

Our test exemplifies how affordable diagnostics can impact upon a key sector with predicted **savings of £265M** per annum for the NHS in a reduction of costly procedures such as colonoscopy with

further savings in late-stage cancer treatments. Globally this can expand to a business which can provide **~ $4.2B cost saving per annum**. This is the future of sustainable healthcare.

The non-invasive diagnostic market is worth over $1B and growing. Competitors have poor early detection and are high cost. What differentiates **CanSense** is its rapid and affordable technology, not reliant on complicated DNA based assays, with no compromise to test accuracy and directed to early disease diagnosis. It has designed a value-based healthcare provision for symptomatic patients and has platform potential to scale into whole population multi-cancer screening.

We are a B2B fee for service provider, setting up a UK centralised laboratory. We have identified Pharma and Private GP practices as our initial customers running in parallel with our continued work with global healthcare providers, including the NHS (CCGs) on behalf of Primary care and Secondary care professionals.

CanSense is seeking £500k seed investment to go alongside a 100% non-dilutive funding commitment of £1.2M which will provide a 24-month runway. The funds will enable hiring of key personnel, laboratory accreditation, assay development, UKCA/CE marking, IP portfolio protection and NICE approval.

CanSense – an award-winning team of world leading experts, demonstrating the required clinical, academic, innovation and business acumen to deliver a test that will transform patient outcomes. With IP secured, the team have the talent to deliver.

Dr Adam Bryant
CEO

20 years working as a senior MD in investment banking. Active angel investor. 4 years working in startups. PhD in theoretical physics.

Professor Dean Harris
Chief Medical Director

Consultant colorectal surgeon in Swansea Bay University Health Board, honorary clinical professor in Swansea Uni. Colorectal MDT lead, Wales Cancer Network. NHSE Clinical Entrepreneur.

Professor Peter Dunstan
Chief Technical Officer

Head of Physics at Swansea University with over 25 years of experience, leading expertise in spectroscopy and bio-spectroscopy. Science Director of the Centre for Nanohealth at Swansea.

Dr Cerys Jenkins
Chief Data Scientist

A dynamic researcher with a strong interdisciplinary background in physics, chemistry and medical research & early cancer diagnostics using spectroscopic analytics combined with AI.